Mining the National Cancer Institute anticancer drug discovery database: Cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity

Molecular Pharmacology

Volumn 53, Issue 2, 1998, Pages 241-251

  Shi, Leming M ^a,c   Myers, Timothy G ^a   Fan, Yi ^a   O'Connor, Patrick M ^a   Paull, Kenneth D ^a   Friend, Stephen H ^a,b   Weinstein, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (N,N DIETHYLAMINO)ETHYLAMINO]CARBONYL 1,2 DIHYDROELLIPTICINE; 9 METHOXY 2 METHYL 1,2 DIHYDROELLIPTICINE; 9 METHOXYELLIPTICINE; ANTINEOPLASTIC AGENT; DATELLIPTINE; ELLIPTICINE; ELLIPTICINE DERIVATIVE; ELLIPTINIUM; ELLIPTINIUM ACETATE; PROTEIN P53; UNCLASSIFIED DRUG;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MUTANT; CENTRAL NERVOUS SYSTEM; CLUSTER ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG CLASSIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0031911557     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.2.241     Document Type: Article

References (41)

1. Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT, and Boyd MR (1994) Anticancer specificity of some ellipticinium salts against human tumors in vitro. J Med Chem 37:2185-2189.
2. Anderson WK, Gopalsamy A, and Reddy PS (1994) Design, synthesis and study of 9-substituted ellipticine and 2-methylellipticinium analogues as potential CNS-selective antitumor agents. J Med Chem 37:1955-1963.
3. Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Paull KD, and Chabner BA (1995) Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 121:495-500.
4. Boyd MR (1997) The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995, in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (Teicher BA, ed) pp 23-42, Humana Press, Totowa, NJ.
5. Bundgaard H (1991) Novel chemical approaches in prodrug design. Drugs Future 16:443-458.
6. Dalton LK, Demerac S, Elmes BC, Lorder JW, Swan JM, and Teitel T (1967) Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[4,3-b]carbazoles. Aust J Chem 20:2715-2727.
7. Devraj R, Barrett JF, Fernandez JA, Katzenellenbogen JA, and Cushman M (1996b) Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates. J Med Chem 39:3367-3374.
8. Devraj R, Jurayi J, Fernandez JA, Barrett JF, and Cushman M (1996a) Synthesis of a series of cytotoxic 2-acyl-l,2-dihydroellipticines which inhibit topoisomerase II. Anti-Cancer Drug Design 11:311-324.
9. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ Jr, and O'Connor PM (1997) Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127-2136.
10. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, and O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830.
11. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654.
12. Goodwin S, Smith AF, and Horning EC (1959) Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 81:1903-1908.
13. Gribble GW (1990) Synthesis and antitumor activity of ellipticine alkaloids and related compounds, in The Alkaloids: Chemistry and Pharmacology (Brossi A, ed) pp 239-352, Academic Press, San Diego.
14. Harris CC (1996) p53 tumor suppressor gene: from the basic research laboratory to the clinic: an abridged historical perspective. Carcinogenesis 17:1187-1198.
15. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991) p53 mutations in human cancers. Science (Washington DC) 253:49-53.
16. Jurayi J, Haugwitz D, Varma RK, Paull KD, Barrett JF, and Cushman M (1994) Design and synthesis ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro. J Med Chem 37:2190-2197.
17. 2-methylellipticinium acetate in human brain and non-brain tumor cell lines. Biochem Pharmacol 49:23-32.
18. Klopman G, Shi LM, and Ramu A (1997) Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52:323-334.
19. Kohn KW, Waring MJ, Glaubiger D, and Friedman CA (1975) Intercalative binding of ellipticine to DNA. Cancer Res 35:71-76.
20. Koo H-M, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, Zarbl H, and Vande Woude GF (1996) Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 56:5211-5216.
21. Koutsoukos AD, Rubinstein LV, Faraggi D, Simon RM, Kalyandrug S, Weinstein JN, Kohn KW, and Paull KD (1994) Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action. Stat Med 13:719-730.
22. Li G, Waltham M, Unsworth E, Treston A, Mushine J, Anderson NL, Kohn KW, and Weinstein JN (1997) Rapid protein identification from two-dimensional polyacryl-amide gels by MALDI mass spectrometry. Electrophoresis 18:391-402.
23. Lowe SW and Jacks T (1997) (Scientific correspondence). Nature (Lond) 385:124-125.
24. Milne GWA, Nicklaus MC, Driscoll JS, Wang S, and Zaharevitz D (1994) National Cancer Institute drug information system 3D database. J Chem Inf Comput Sci 34:1219-1224.
25. Monks A, Scudiero DA, Shoemaker RH, Paull KD, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campell H, Mayo J, and Boyd MR (1991) Feasibility of a high-flux anticancer screen using a diverse panel of cultured human tumor lines. J Natl Cancer Inst 83:757-766.
26. Myers TG, Waltham M, Li G, Buolamwini JK, Scudiero DA, Rubinstein LV, Paull KD, Sausville EA, Anderson NL, and Weinstein JN (1997) A protein expression database for the molecular pharmacology of cancer. Electrophoresis 18:647-653.
27. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, and Kohn KW (1997) Characterization of the p53-tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
28. Paull KD, Hamel E, and Malspeis L (1995) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute, in Cancer Chemotherapeutic Agents (Foye WO, ed) pp 9-45, American Chemical Society, Washington, DC.
29. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092.
30. Rogers D and Hopfinger AJ (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci 34:854-866.
31. Sainsbury M (1990) Ellipticines, in The Chemistry of Antitumor Agents (Wilman D, ed) pp 410-435, Chapman and Hall, New York.
32. Shi LM, Fan Y, Myers TG, Paull KD, and Weinstein JN (1997a) Mining the anticancer activity database generated by the NCI anticancer drug discovery program using statistical and artificial intelligence techniques. Mathematic Model Sci Comput 8, in press.
33. Shi LM, Fan Y, Myers TG, and Weinstein JN (1997b) Genetic function approximation in the molecular pharmacology of cancer. Proceedings of the 1997 International Conference on Neural Networks (ICNN '97), Houston, TX, pp 2490-2493. Institute of Electrical and Electronics Engineers, Piscataway, NJ.
34. Shi LM, Fan Y, Myers TG, O'Conner PM, Paull KD, Friend SH, and Weinstein JN (1998) Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogs. J Chem Inf Comput Sci 38, in press.
35. Shimamoto T, Imajo S, Honda T, Yoshimura S, and Ishiguro M (1996) Structure-activity relationship study on N-glycosyl moieties through model building of DNA and ellipticine N-glycoside complex. Bioorg Med Chem Lett 6:1331-1334.
36. van Osdol WW, Myers TG, Paull KD, Kohn KW, and Weinstein JN (1994) Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J Natl Cancer Inst 86:1853-1859.
37. Varia SA, Schuller S, Sloan KB, and Stella VJ (1984) Phenytoin prodrugs. III: water-soluble prodrugs for oral and/or parenteral use. J Pharm Sci 73:1068-1073.
38. Vistica DT, Kenney S, Hursey ML, and Boyd MR (1994) Cellular uptake as a determinant of cytotoxicity of quaternized ellipticines to human brain tumor cells. Biochem Biophys Res Commun 200:1762-1768.
39. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJ, and Paull KD (1992) Neural computing in cancer drug development: predicting mechanism of action. Science (Washington DC) 258:447-451.
40. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr., Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, and Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC) 275:343-349.
41. Weinstein JN, Myers T, Buolamwini J, Raghavan K, van Osdol W, Licht J, Viswanadhan VN, Kohn KW, Rubinstein LV, Koutsoukos AD, Monks A, Scudiero DA, Anderson NL, Zaharevitz D, Chabner BA, Grever MR, and Paull KD (1994) Predictive statistics and artificial intelligence in the U. S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS. Stem Cells 12:13-22.